Efficacy and Safety of Study Drug NS-229 in Treatment of Eosinophilic Granulomatosis with Polyangiitis

The main purpose of this study is to learn how well the investigational drug NS-229 works and how safe NS-229 is compared with placebo. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) to treat EGPA.

Study Duration: Approximately 9 months